{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T06:02:57Z","timestamp":1768888977942,"version":"3.49.0"},"reference-count":24,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medicina Intensiva"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1016\/j.medin.2016.10.008","type":"journal-article","created":{"date-parts":[[2016,12,27]],"date-time":"2016-12-27T18:03:37Z","timestamp":1482861817000},"page":"475-482","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Reduced thrombin activatable fibrinolysis inhibitor and enhanced proinflammatory cytokines in acute coronary syndrome"],"prefix":"10.1016","volume":"41","author":[{"given":"H.","family":"Pang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"X.","family":"Gong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"X.","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.medin.2016.10.008_bib0125","doi-asserted-by":"crossref","first-page":"396","DOI":"10.21037\/cdt.2016.06.01","article-title":"Pathology of coronary atherosclerosis and thrombosis","volume":"6","author":"Otsuka","year":"2016","journal-title":"Cardiovasc Diagn Ther"},{"key":"10.1016\/j.medin.2016.10.008_bib0130","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.thromres.2011.12.026","article-title":"Thrombosis and acute coronary syndrome","volume":"129","author":"Abbate","year":"2012","journal-title":"Thromb Res"},{"key":"10.1016\/j.medin.2016.10.008_bib0135","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1111\/jth.12674","article-title":"A role for arginine-12 in thrombin-thrombomodulin-mediated activation of thrombin-activatable fibrinolysis inhibitor","volume":"12","author":"Plug","year":"2014","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.medin.2016.10.008_bib0140","doi-asserted-by":"crossref","first-page":"210","DOI":"10.2174\/187221412802481748","article-title":"Role of thrombin activatable fibrinolysis inhibitor in endocrine and cardiovascular disorders: an update","volume":"6","author":"Akinci","year":"2012","journal-title":"Recent Pat Endocr Metab Immune Drug Discov"},{"key":"10.1016\/j.medin.2016.10.008_bib0145","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1055\/s-0037-1613349","article-title":"Thrombin activatable fibrinolysis inhibitor (TAFI) levels in patients with coronary artery disease investigated by angiography","volume":"88","author":"Schroeder","year":"2002","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.medin.2016.10.008_bib0150","first-page":"880","article-title":"Risk of acute coronary artery disease associated with functional thrombin activatable fibrinolysis inhibitor plasma level","volume":"89","author":"Santamar\u00eda","year":"2004","journal-title":"Haematologica"},{"key":"10.1016\/j.medin.2016.10.008_bib0155","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1161\/01.ATV.0000015445.22243.F4","article-title":"Plasma thrombin-activatable fibrinolysis inhibitor antigen concentration and genotype in relation to myocardial infarction in the North and South of Europe","volume":"22","author":"Juhan","year":"2002","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.medin.2016.10.008_bib0160","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/j.metabol.2004.02.004","article-title":"Low-grade inflammation may play a role in the etiology of the metabolic syndrome in patients with coronary heart disease: the HIFMECH study","volume":"53","author":"Yudkin","year":"2004","journal-title":"Metabolism"},{"key":"10.1016\/j.medin.2016.10.008_bib0165","doi-asserted-by":"crossref","first-page":"36","DOI":"10.4161\/viru.25436","article-title":"Host innate immune responses to sepsis","volume":"5","author":"Wiersinga","year":"2014","journal-title":"Virulence"},{"key":"10.1016\/j.medin.2016.10.008_bib0170","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1055\/s-0034-1398376","article-title":"Coagulation in patients with severe sepsis","volume":"41","author":"Levi","year":"2015","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.medin.2016.10.008_bib0175","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.1093\/eurheartj\/ehm355","article-title":"Universal definition of myocardial infarction","volume":"28","author":"Thygesen","year":"2007","journal-title":"Eur Heart J"},{"key":"10.1016\/j.medin.2016.10.008_bib0180","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/j.amjmed.2008.08.020","article-title":"Impact of changing definitions for myocardial infarction: a report from the AMIS registry","volume":"121","author":"Urban","year":"2008","journal-title":"Am J Med"},{"key":"10.1016\/j.medin.2016.10.008_bib0185","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/S0049-3848(00)00411-4","article-title":"Thrombin-activatable fibrinolysis inhibitor (TAFI, plasma procarboxypeptidase B, procarboxypeptidase R, procarboxypeptidase U)","volume":"101","author":"Bouma","year":"2001","journal-title":"Thromb Res"},{"key":"10.1016\/j.medin.2016.10.008_bib0190","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.2174\/138955709789055216","article-title":"Recent developments in thrombin-activatable fibrinolysis inhibitor research","volume":"9","author":"Marx","year":"2009","journal-title":"Mini Rev Med Chem"},{"key":"10.1016\/j.medin.2016.10.008_bib0195","doi-asserted-by":"crossref","first-page":"214680","DOI":"10.1155\/2015\/214680","article-title":"Impaired fibrinolysis in angiographically documented coronary artery disease","volume":"2015","author":"Fernandes","year":"2015","journal-title":"Adv Hematol"},{"key":"10.1016\/j.medin.2016.10.008_bib0200","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.thromres.2007.03.021","article-title":"Comparison of two immunochemical assays for measuring thrombin-activatable fibrinolysis inhibitor concentration with a functional assay in patients with acute coronary syndrome","volume":"121","author":"Skeppholm","year":"2007","journal-title":"Thromb Res"},{"key":"10.1016\/j.medin.2016.10.008_bib0205","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/j.1538-7836.2009.03663.x","article-title":"The decrease in procarboxypeptidase U (TAFI) concentration in acute ischemic stroke correlates with stroke severity, evolution and outcome","volume":"8","author":"Brouns","year":"2010","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.medin.2016.10.008_bib0210","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1182\/blood.V97.7.2053","article-title":"Identification of polymorphisms in the promoter and the 3\u2032 region of the TAFI gene: evidence that plasma TAFI antigen levels are strongly genetically controlled","volume":"97","author":"Henry","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.medin.2016.10.008_bib0215","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.thromres.2009.07.004","article-title":"Thrombin-activatable fibrinolysis inhibitor genetic polymorphisms as markers of the type of acute coronary syndrome","volume":"124","author":"T\u00e0ssies","year":"2009","journal-title":"Thromb Res"},{"key":"10.1016\/j.medin.2016.10.008_bib0220","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1160\/TH14-08-0653","article-title":"Pro-inflammatory cytokines reduce human TAFI expression via tristetraprolin-mediated mRNA destabilisation and decreased binding of HuR","volume":"114","author":"Komnenov","year":"2015","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.medin.2016.10.008_bib0225","first-page":"61","article-title":"Regulation of tissue inflammation by thrombin-activatable carboxypeptidase B (or TAFI)","volume":"632","author":"Leung","year":"2008","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.medin.2016.10.008_bib0230","first-page":"364","article-title":"Micro-ultrasonographic imaging of atherosclerotic progression and correlation with inflammatory markers in apolipoprotein-E knockout mice","volume":"38","author":"Li","year":"2011","journal-title":"Tex Heart Inst J"},{"key":"10.1016\/j.medin.2016.10.008_bib0235","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.atherosclerosis.2010.06.001","article-title":"Gax gene transfer inhibits vascular remodeling induced by adventitial inflammation in rabbits","volume":"212","author":"Liu","year":"2010","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.medin.2016.10.008_bib0240","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1177\/039463201302600403","article-title":"Impact of mast cells on the skin","volume":"26","author":"Kritas","year":"2013","journal-title":"Int J Immunopathol Pharmacol"}],"container-title":["Medicina Intensiva"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0210569116302480?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0210569116302480?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,17]],"date-time":"2019-09-17T00:37:12Z","timestamp":1568680632000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0210569116302480"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":24,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["S0210569116302480"],"URL":"https:\/\/doi.org\/10.1016\/j.medin.2016.10.008","relation":{},"ISSN":["0210-5691"],"issn-type":[{"value":"0210-5691","type":"print"}],"subject":[],"published":{"date-parts":[[2017,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reduced thrombin activatable fibrinolysis inhibitor and enhanced proinflammatory cytokines in acute coronary syndrome","name":"articletitle","label":"Article Title"},{"value":"Medicina Intensiva","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medin.2016.10.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Espa\u00f1a, S.L.U. y SEMICYUC. All rights reserved.","name":"copyright","label":"Copyright"}]}}